Porsolt & Partners Pharmacology, a France-based contract research organization providing specialized animal pharmacology research services over a wide range of therapeutic domains, has signed a co-marketing agreement with Singapore-based preclinical CRO, Maccine. The latter provides contract services in pharmacology (safety and efficacy) in non-human primates.
Under the terms of this agreement, the two companies will promote their collective preclinical contract research service lines to the global pharmaceutical and biotechnology industry.
For Porsolt & Partners Pharmacology, Martine Lemaire, senior director of scientific and business development explained: "this strategic partnership will bring new and compelling synergies to our business. Providing a full package of flexible and tailored quality solutions is the key to satisfaction of our sponsors. Porsolt & Partners Pharmacology is committed to staying at the forefront of its field of acknowledged expertise and Maccine's positioning with primate research will extend our range of services in pharmacology and enable us to better meet the needs of our sponsors."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze